VIA
NBIX icon

Vident Investment Advisory’s Neurocrine Biosciences NBIX Stock Holding History

Vident Investment Advisory’s Portfolio NBIX Stock Details NBIX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q4 		– Sell
-4,338
Closed -$416K – 1226
2021
Q3 		$416K Sell
4,338
-615
-12% -$58.1K 0.01% 926
2021
Q2 		$482K Buy
4,953
+279
+6% +$26.7K 0.01% 843
2021
Q1 		$455K Sell
4,674
-369
-7% -$38.7K 0.02% 815
2020
Q4 		$483K Sell
5,043
-2,698
-35% -$261K 0.02% 727
2020
Q3 		$744K Sell
7,741
-2,523
-25% -$292K 0.04% 572
2020
Q2 		$1.25M Buy
10,264
+3,805
+59% +$420K 0.07% 400
2020
Q1 		$559K Sell
6,459
-75
-1% -$7.34K 0.04% 552
2019
Q4 		$702K Sell
6,534
-824
-11% -$86.3K 0.04% 466
2019
Q3 		$663K Buy
7,358
+747
+11% +$69.8K 0.06% 252
2019
Q2 		$558K Buy
6,611
+639
+11% +$52.5K 0.04% 297
2019
Q1 		$526K Buy
5,972
+1,512
+34% +$126K 0.03% 558
2018
Q4 		$318K Buy
4,460
+476
+12% +$45.6K 0.02% 697
2018
Q3 		$490K Sell
3,984
-640
-14% -$72.6K 0.02% 701
2018
Q2 		$454K Buy
4,624
+52
+1% +$4.66K 0.02% 689
2018
Q1 		$345K Buy
4,572
+1,898
+71% +$160K 0.01% 756
2017
Q4 		$207K Buy
+2,674
New +$182K 0.01% 763

Other funds holding NBIX

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Janus Henderson Group
Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
BG
Bellevue Group Kuesnacht, Switzerland $4.2B AUM 54.85% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return
Bank of New York Mellon
Bank of New York Mellon New York $544B AUM 28.31% 1-Year Est. Return
EVM
Eaton Vance Management Boston, Massachusetts $67.5B AUM 11.44% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return

Vident Investment Advisory's NBIX Position: Q4 2021 in Review

Vident Investment Advisory sold out of Neurocrine Biosciences (NBIX) in Q4 2021, closing a stake of 4,338 shares — an estimated $416K sold.

Vident Investment Advisory first reported a position in NBIX in Q4 2017 and held it in 16 quarters. The position peaked at $1.25M in Q2 2020. 405 funds tracked by Wall St. Rank hold NBIX as of Q4 2021.

  • Vident Investment Advisory reported no remaining Neurocrine Biosciences position as of Q4 2021 after selling out during the quarter.
  • Vident Investment Advisory sold 4,338 Neurocrine Biosciences shares in Q4 2021, an estimated $416K.
  • Vident Investment Advisory first reported a position in Neurocrine Biosciences in Q4 2017 and held it in 16 quarters.
  • Vident Investment Advisory's Neurocrine Biosciences position peaked at $1.25M in Q2 2020.
  • 405 funds tracked by Wall St. Rank held Neurocrine Biosciences as of Q4 2021.

Based on Vident Investment Advisory's 13F filing for Q4 2021, filed 14 Feb 2022.